| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-08-13 22:41:35 UTC |
|---|
| Update Date | 2022-03-07 02:49:21 UTC |
|---|
| HMDB ID | HMDB0004631 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Formebolone |
|---|
| Description | Formebolone is a synthetic anabolic steroid. It is suspected of misuse in sports and therefore tested for in regular screening of athletes. The desire to artificially enhance physical performance in order to increase the chances to win in sports competition is supposedly as old as mankind itself. Already during the ancient Olympic Games, in approximately 200 B.C., athletes used concoctions of mushrooms and plant seeds, as well as special diets including bovine and canine testicles, as reported by Philostratos and Galen. The attempt to improve the power and strength of racing animals also has a long history, as it has been reported that the ancient Romans fed their horses so-called 'Hydromel', a mixture of honey and water, in order to increase endurance. The manipulation of the capacities of an athlete or animal has been referred to as doping since 1889, when this term, originating from a dialect spoken in the south-eastern region of Africa, was included in a British dictionary. With the athlete Linton, the first authentic doping-related death occurred in 1886 during a cycle race (Paris-Bordeaux), caused by an overdose of caffeine. (For a more complete review on doping see PMID: 15808003 ). |
|---|
| Structure | [H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C(C=O)=C[C@]12C InChI=1S/C21H28O4/c1-19-9-12(11-22)16(23)8-13(19)4-5-14-15-6-7-21(3,25)20(15,2)10-17(24)18(14)19/h8-9,11,14-15,17-18,24-25H,4-7,10H2,1-3H3/t14-,15-,17+,18+,19-,20-,21-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (11a,17b)-11,17-Dihydroxy-17-methyl-3-oxo-androsta-1,4-diene-2-carboxaldehyde | HMDB | | 11a,17b-Dihydroxy-17-methyl-3-oxo-androsta-1,4-diene-2-carboxaldehyde | HMDB | | 11a,17b-Dihydroxy-17-methyl-3-oxoandrosta-1,4-diene-2-carboxaldehyde | HMDB | | 2-Formyl-11a-hydroxy-D1-methyltestosterone | HMDB | | 2-Formyl-17a-methylandrosta-1,4-dien-11a,17b-diol-3-one | HMDB | | 2-Formyl-17a-methylandrosta-1,4-diene-11a,17b-dihydroxy-3-one | HMDB | | 2-Formyl-17a-methylandrosta-1,4-diene-11a,17b-diol-3-one | HMDB | | Esiclene | HMDB, MeSH | | Formyldienolone | HMDB, MeSH | | 2-Formyl-17 alpha-methylandrosta-1,4-diene-11 alpha,17 beta-diol-3-one | MeSH, HMDB | | Formyldienolone, (11 beta,17beta)-isomer | MeSH, HMDB | | Formildienolone | MeSH, HMDB | | Formebolone | MeSH |
|
|---|
| Chemical Formula | C21H28O4 |
|---|
| Average Molecular Weight | 344.4446 |
|---|
| Monoisotopic Molecular Weight | 344.198759384 |
|---|
| IUPAC Name | (1S,2R,10S,11S,14S,15S,17R)-14,17-dihydroxy-2,14,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-diene-4-carbaldehyde |
|---|
| Traditional Name | formebolone |
|---|
| CAS Registry Number | 2454-11-7 |
|---|
| SMILES | [H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C(C=O)=C[C@]12C |
|---|
| InChI Identifier | InChI=1S/C21H28O4/c1-19-9-12(11-22)16(23)8-13(19)4-5-14-15-6-7-21(3,25)20(15,2)10-17(24)18(14)19/h8-9,11,14-15,17-18,24-25H,4-7,10H2,1-3H3/t14-,15-,17+,18+,19-,20-,21-/m0/s1 |
|---|
| InChI Key | AMVODTGMYSRMNP-GNIMZFFESA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Androstane steroids |
|---|
| Direct Parent | Androgens and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Androgen-skeleton
- 3-oxo-delta-1,4-steroid
- 3-oxosteroid
- Hydroxysteroid
- Oxosteroid
- 11-alpha-hydroxysteroid
- 11-hydroxysteroid
- 17-hydroxysteroid
- Delta-1,4-steroid
- Cyclic alcohol
- Tertiary alcohol
- Secondary alcohol
- Ketone
- Cyclic ketone
- Aldehyde
- Organooxygen compound
- Alcohol
- Organic oxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 209 - 212 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.97 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 15.1243 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.07 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2748.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 299.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 197.9 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 182.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 170.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 691.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 756.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 82.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1191.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 497.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1610.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 442.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 464.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 270.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 462.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 14.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Formebolone,1TMS,isomer #1 | C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(=O)C(C=O)=C[C@]4(C)[C@H]3[C@H](O)C[C@@]21C | 3226.4 | Semi standard non polar | 33892256 | | Formebolone,1TMS,isomer #2 | C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C(C=O)=C[C@]4(C)[C@H]3[C@H](O[Si](C)(C)C)C[C@@]21C | 3146.5 | Semi standard non polar | 33892256 | | Formebolone,2TMS,isomer #1 | C[C@]1(O[Si](C)(C)C)CC[C@H]2[C@@H]3CCC4=CC(=O)C(C=O)=C[C@]4(C)[C@H]3[C@H](O[Si](C)(C)C)C[C@@]21C | 3128.8 | Semi standard non polar | 33892256 | | Formebolone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)C(C=O)=C[C@]4(C)[C@H]3[C@H](O)C[C@@]21C | 3460.1 | Semi standard non polar | 33892256 | | Formebolone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@H]1C[C@@]2(C)[C@@H](CC[C@]2(C)O)[C@@H]2CCC3=CC(=O)C(C=O)=C[C@]3(C)[C@H]21 | 3389.6 | Semi standard non polar | 33892256 | | Formebolone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@H]1C[C@@]2(C)[C@@H](CC[C@]2(C)O[Si](C)(C)C(C)(C)C)[C@@H]2CCC3=CC(=O)C(C=O)=C[C@]3(C)[C@H]21 | 3583.3 | Semi standard non polar | 33892256 |
|
|---|